Syndax Pharma (SNDX) stock rose after Kura Oncology (KURA) posted a mid-stage trial win for a leukemia drug is similar to ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。

Eligible patients included adults with AML or MDS, a Karnofsky performance status ≥60%, and age ≥50 years or a hematopoietic cell transplantation comorbidity index score >2. Compared with ...

were presented at the 2023 EHA Congress and showed a 35% complete remission (CR') rate in 20 patients with NPM1-mutant AML at the 600-mg dose, as well as a composite CR rate and an overall ...

Acute promyelocytic leukemia (APL) presenting solely as myeloid sarcoma (MS) is extremely rare. This report describes a 53-year-old male who presented with low back pain and a movement disorder in his ...

Risk categorization of AML based on karyotyping of leukemic blasts has become routine. Mutations in NPM1, CCAAT enhancer-binding protein-α (with double-mutations) and FCT3-internal tandem ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML ... On the other hand, NPM1 mutation also was noted as a favorable prognostic factor.

Blood does more than just carry oxygen and nutrients. Its many “markers,” known as antigens, can trigger unexpected responses. Most folks have heard about the blood groups A, B, and O, and the Rh ...